India, May 29 -- image credit- shutterstock

AstraZeneca India Pharma Ltd. (AZPIL), a global, science-led, patient focused pharmaceutical company, has received approval from the Central Drugs Standard Control Organisation (CDSCO), for the import, sale, and distribution ofOsimertinib 40mg and 80mg tablets for an additional indication.

The approval marks a critical step forward with Osimertinib as monotherapy in the treatment of patients with locally advanced, unresectable (Stage III) Non-Small Cell Lung Cancer (NSCLC) harbouring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.

This new indication represents a first-in-class tre...